

Press Release

NutrigeneAI Co-Founder Professor Jack Wong Invited to Speak at BIOHK2025, Showcasing Breakthroughs in Vascular Regeneration and CGT Innovation

September 2025, Hong Kong–

Professor Jack Wong, Associate Professor at the School of Life Sciences of The Chinese University of Hong Kong (CUHK) and Co-Founder of NutrigeneAI Biotech Limited, has been invited to speak at BIOHK2025, one of Asia's premier biotechnology forums and exhibitions, taking place on September 10–13, 2025 at the Hong Kong Convention and Exhibition Centre. The event will bring together world-renowned scientists, industry leaders, investors, and government representatives to explore the future of biotechnology.



A Global Biotechnology Showcase


BIOHK2025 is set to feature more than 250 sponsors and exhibitors, over 100 world-class speakers, 20 thematic conferences, and 30 project roadshows. Distinguished speakers include Nobel laureates, international academics, senior executives from multinational pharmaceutical companies, and leading biotech investors. The conference will cover a wide range of frontier topics including cell and gene therapy (CGT), AI-driven drug discovery, regenerative medicine, IVD diagnostics, brain-machine interfaces, and modern Chinese medicine. Supported by the Hong Kong SAR Government, which has allocated HK\$10 billion to health and biotech innovation, the event has become a critical platform for global collaboration and commercialization.

BIOHK2025 Themes and Topics


Regenerative Medicine **Stem Cell** Antiaging **Neuroscience**
Exosome Science **GLP-1** Wearable Devices Cancer and Disease Research
Gene Editing Chronic Diseases mRNA Vaccines
Infectious Disease Aging Populations Woman Scientists Traditional Chinese Medicine
Disease Prevention Ophthalmology **Innovative Drugs**
Peptides **AI & Robotics** Brain-Computer Interfaces
Smart Hospital Anti-inflammatory Drug Discovery **Diagnosis**
IPO Mergers & acquisitions **IVD** Ethics and Regulations
Decentralization of Science Cellular Immunotherapy **POCT**
Longevity Nutraceuticals Microbiota and Health Personalized Medicine and Genomics
Antibody Drug Quantum Science **CRO & CMO** ...

Professor Wong’s Contribution

As a keynote speaker, Professor Wong will focus on the research and translational pathways of CGT-based therapies, sharing insights from NutrigeneAI’s groundbreaking work in vascular regeneration. The company is advancing innovative solutions using iPSC-derived endothelial cells (iPSC-ECs) and cytokine-based technologies to develop a first-in-class therapy that can restore blood flow and significantly reduce the risk of amputation for patients with diabetic foot ulcers and peripheral artery disease (PAD).



In his talk, Professor Wong will also highlight NutrigeneAI’s experiences in intellectual property development, pre-clinical research, and strategies for clinical translation, providing valuable perspectives on how to accelerate the journey from laboratory research to patient treatment.



Opportunities for Global Collaboration

Through BIOHK2025, NutrigeneAI aims to:

- Engage with PE/VC investors to support upcoming pre-clinical and clinical programs.
- Connect with government agencies and biotech parks in mainland China and across the Greater Bay Area to explore development opportunities.

- Establish partnerships with leading CRO and CDMO service providers, such as ProBio, to strengthen its value chain.
- Expand its reach into emerging markets across Southeast Asia, mainland China, and beyond.

Looking Ahead

“We are honored to be invited to BIOHK2025, a global stage where science, industry, and investment converge,” said Professor Jack Wong, Co-Founder of NutrigeneAI. “Our mission at NutrigeneAI is to transform scientific breakthroughs into accessible and affordable therapies that improve patients’ lives while positioning Hong Kong and the Greater Bay Area as a global hub for biomedical innovation.”

NutrigeneAI is currently accelerating the development of its vascular regeneration and CGT pipeline, with plans to initiate clinical trials within the next three to five years and achieve commercialization by 2033–2035. With BIOHK2025 providing a powerful platform for international exchange, NutrigeneAI is ready to collaborate with global partners to shape the future of biotechnology.

---Ends---

Media Contact:

Communications Office

NutrigeneAI Biotech Limited

coby.ke@nutrigeneai.com